BTK inhibitors in particular are also associated with poor antibody-mediated response rates to influenza vaccination in patients with CLL [35,36] (rates of 7–26%) and decreased immune responses to the anti-hepatitis B vaccine, HepB-CpG19 [42]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.